Sarepta Therapeutics（SRPT）今日盘前股价大跌5.11%，引发了市场广泛关注。
消息面上，公司首席执行官道格拉斯·英格拉姆已决定在2026年底或继任者任命后卸任，这一领导层变动带来了不确定性。更为关键的是，公司核心产品基因疗法Elevidys面临严重安全挑战，据报道已导致两名患者死亡，且销售额出现下滑。美国食品和药物管理局（FDA）已要求Sarepta主动停止该疗法的出货，并正对相关死亡事件进行调查。此外，Elevidys的标签已被加上FDA最严重的安全警告，并伴有严格的治疗后监测要求。公司还宣布将裁员500人，并停止其他几种肢腰肌营养不良症基因疗法的开发。这些多重负面因素严重打击了投资者信心，导致了抛售行为。
公司股价在去年已累计下跌82%，此次盘前大跌进一步反映了市场对其未来业务前景与产品管线安全的深切担忧。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.